Cargando…
Biosimilars in India; Current Status and Future Perspectives
Many key biologics are scheduled to lose their patent by the year 2020, which will provide the opportunity to other biopharmaceutical companies to develop the similar biologics. Biosimilar or similar biologic used has increased in the recent year following the approval of the first biosimilar in ear...
Autores principales: | Meher, Bikash R., Balan, Sakthi, Mohanty, Rashmi R., Jena, Monalisa, Das, Smita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394151/ https://www.ncbi.nlm.nih.gov/pubmed/30906134 http://dx.doi.org/10.4103/jpbs.JPBS_167_18 |
Ejemplares similares
-
Vaccine pharmacovigilance in India: Current context and future perspective
por: Meher, Bikash Ranjan
Publicado: (2019) -
Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
por: Park, Sang Hyoung, et al.
Publicado: (2020) -
Biosimilars: Current perspectives and future implications
por: Misra, Monika
Publicado: (2012) -
Comparative Study of the Effects of Azilsartan and Telmisartan on Insulin Resistance and Metabolic Biomarkers in Essential Hypertension Associated With Type 2 Diabetes Mellitus
por: Meher, Bikash R, et al.
Publicado: (2022) -
Current perspectives on biosimilars
por: Agbogbo, Frank K., et al.
Publicado: (2019)